Eldepryl Side Effects
Generic Name: selegiline
Note: This document contains side effect information about selegiline. Some of the dosage forms listed on this page may not apply to the brand name Eldepryl.
Common side effects of Eldepryl include: dizziness and nausea. Other side effects include: abdominal pain. See below for a comprehensive list of adverse effects.
For the Consumer
Applies to selegiline: oral capsule, oral tablet, oral tablet disintegrating
Other dosage forms:
Along with its needed effects, selegiline (the active ingredient contained in Eldepryl) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking selegiline:
- Twitching, twisting, uncontrolled repetitive movements of the tongue, lips, face, arms, or legs
- Blurred vision
- chest pain
- decreased urine
- difficult or labored breathing
- difficulty with swallowing
- dry mouth
- feeling sad or empty
- increased thirst
- irregular heartbeat
- large, flat, blue or purplish patches in the skin
- loss of appetite
- loss of interest or pleasure
- mood changes
- muscle pain or cramps
- nausea or vomiting
- numbness or tingling in the hands, feet, or lips
- pounding in the ears
- seeing, hearing, or feeling things that are not there
- shakiness and unsteady walk
- shakiness in the legs, arms, hands, or feet
- sleepiness or unusual drowsiness
- slow or fast heartbeat
- swelling or inflammation of the mouth
- tightness in the chest
- trouble concentrating
- trouble sleeping
- unsteadiness, trembling, or other problems with muscle control or coordination
- unusual tiredness or weakness
Incidence Not Known
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- overactive reflexes
- poor coordination
- talking or acting with excitement you cannot control
Get emergency help immediately if any of the following symptoms of overdose occur while taking selegiline:
Symptoms of Overdose
- chest pain
- difficulty opening the mouth or lockjaw
- dizziness (severe) or fainting
- fast or irregular pulse (continuing)
- high fever
- high or low blood pressure
- severe spasm where the head and heels are bent backward and the body arched forward
- troubled breathing
Some side effects of selegiline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Dry skin
- hives, itching, or skin rash
- itching, scaling, severe redness, soreness, or swelling of the skin
- runny nose
- stuffy nose
- trouble sleeping
- Acid or sour stomach
- back pain
- bloated or full feeling
- body aches or pain
- difficulty having a bowel movement (stool)
- difficulty with moving
- dryness or soreness of the throat
- excess air or gas in the stomach or intestines
- joint pain
- leg cramps
- muscle aching or cramping
- muscle pains or stiffness
- passing gas
- stomach discomfort, upset, or pain
- swollen joints
- tender, swollen glands in the neck
- tooth problems
- voice changes
For Healthcare Professionals
Applies to selegiline: compounding powder, oral capsule, oral tablet, oral tablet disintegrating, transdermal film extended release
In prospective pre-marketing studies, the most commonly reported side effects leading to treatment discontinuation with selegiline (the active ingredient contained in Eldepryl) oral tablets were, in decreasing order of frequency, nausea, hallucinations, confusion, depression, loss of balance, insomnia, orthostatic hypotension, increased akinetic involuntary movements, agitation, arrhythmia, bradykinesia, chorea, delusions, hypertension, new or increased angina pectoris, and syncope.
In clinical trials with selegiline orally disintegrating tablets, the most commonly reported side effects leading to treatment discontinuation were dizziness, chest pain, accidental injury, and myasthenia. The relative risk for treatment-emergent hypertension and orthostatic or postural hypotension was reported as being at least 2 fold greater in patients 65 years or older compared to those younger than 65 years. Patients over 65 years were also reported at an increased risk for somnolence compared to younger patients.
In clinical trials with selegiline transdermal patches, application site reaction was reported as the side effect that lead to treatment discontinuation in at least 1% of patients at a rate at least twice that of placebo.
Insomnia and sleep disorder were reported as very common side effects with selegiline (the active ingredient contained in Eldepryl) in double-blind placebo-controlled clinical trials at a higher frequency when used as adjunctive therapy with levodopa in the earlier phases of Parkinson's disease. Insomnia was also reported as a very common side effect in placebo-controlled clinical trials for major depressive disorder with transdermal selegiline.
Parkinson's disease patients treated with dopamine agonists and/or other dopaminergic treatments such as selegiline have been reported as exhibiting impulse control disorders such as pathological gambling, increased libido, hypersexuality, compulsive spending/buying, and binge eating. There have been very few cases reported with selegiline. In some cases, dose reduction or treatment discontinuation led to cessation of impulse control disorders.
Postmarketing reports have indicated that patients taking this drug may experience new or worsening mental status and behavioral changes, such as psychotic-like behavior, particularly after starting therapy or increasing the dose. Certain medications used to treat psychosis (e.g., dopamine antagonists) may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of selegiline. Transient high and bruxism were reported at doses greater than 10 mg per day.
Anxiety was reported as a very common side effect with selegiline in double-blind placebo-controlled clinical trials when used as adjunctive therapy with levodopa in the earlier phases of Parkinson's disease.
Antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. An increased risk of suicidal thinking and behavior in children, adolescents, and young adults (aged 18 to 24 years) with major depressive disorder (MDD) and other psychiatric disorders has been reported with short-term use of antidepressant drugs.
Adult and pediatric patients receiving antidepressants for MDD, as well as for psychiatric and nonpsychiatric indications, have reported symptoms that may be precursors to emerging suicidality, including anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania. Causality has not been established.[Ref]
Very common (10% or more): Insomnia
Common (1% to 10%): Anxiety/tension, confusion, depression, euphoria, hallucinations, illusion, sleeping disorders, vivid dreams
Uncommon (0.1% to 1%): Abnormal dreams, agitation, manic reaction, mild transient irritability, mood change, psychoses
Frequency not reported: Apathy, delusions, disorientation, dreams/nightmares, hollow feeling, overstimulation, personality change, sleep disturbance, transient high, transient irritability
Postmarketing reports: Abnormal thinking, aggressive reaction, bruxism, delirium, impulse control disorders and compulsions, nervousness, paranoid reaction, paroniria, psychotic-like behavior[Ref]
Very common (10% or more): Dizziness/lightheadedness/fainting
Common (1% to 10%): Abnormal movements (e.g., dyskinesias, bradykinesia, akinesia), ataxia, headache, impaired balance, lethargy, somnolence, syncope, tremor
Frequency not reported: Chorea, drowsiness, dyskinesia, dystonic symptoms, facial grimace, festination, impaired memory, increased apraxia, involuntary movements, migraine, myoclonic jerks, numbness of toes/fingers, restlessness, speech affected, supraorbital pain, tardive dyskinesia
Postmarketing reports: Abnormal gait, cerebrovascular disorder, coma, convulsions, hypertonia, involuntary muscle contractions, neuroleptic malignant syndrome, serotonin syndrome, taste disturbance[Ref]
There have been reports of falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes resulted in accidents, in Parkinson's disease patients treated with this drug. These reports have occurred in a setting of pre-existing somnolence.
Impaired memory and myoclonic jerks were reported at doses greater than 10 mg per day. Seizure in dialyzed chronic renal failure in a patient treated with selegiline on concomitant medications has been reported in postmarketing experience.
A symptom complex resembling the neuroleptic malignant syndrome, with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in, antiparkinson therapy.
There have been postmarketing reports of fatal and non-fatal cases of serotonin syndrome with concomitant use of this drug with antidepressants.
Headache was reported as a very common side effect in placebo-controlled clinical trials for major depressive disorder with transdermal selegiline.[Ref]
This drug inhibits the catabolism of dietary amines such as tyramine, and has the potential to produce a hypertensive crisis following the ingestion of tyramine-rich foods or beverages.
Postural hypotension was reported with selegiline (the active ingredient contained in Eldepryl) in double-blind placebo-controlled clinical trials at a higher frequency when used as adjunctive therapy with levodopa in the earlier phases of Parkinson's disease compared to the late phase. Palpitation was also reported as a very common side effect in the earlier phases of Parkinson's disease in these trials.[Ref]
Very common (10% or more): Postural hypotension
Frequency not reported: Peripheral edema, hematoma, tachycardia
Postmarketing reports: Flushing, myocardial infarction[Ref]
Constipation was reported as a very common side effect with selegiline (the active ingredient contained in Eldepryl) in double-blind placebo-controlled clinical trials when used as adjunctive therapy with levodopa in the earlier phases of Parkinson's disease.[Ref]
Very common (10% or more): Dry mouth, irritation of the buccal mucosa (orally disintegrating tablet), mouth ulceration, nausea, stomatitis
Increased energy was reported at doses greater than 10 mg per day.
Vertigo was a very common side effect reported with selegiline (the active ingredient contained in Eldepryl) in double-blind placebo-controlled clinical trials when used as adjunctive therapy with levodopa compared with its use as monotherapy.[Ref]
Very common (10% or more): Fatigue
Common (1% to 10%): Fall, pain, vertigo
Frequency not reported: Chills, generalized ache, falling down, freezing, heavy leg, increased energy, malaise, tinnitus, tiredness, weakness
Postmarketing reports: Asthenia, death, fever[Ref]
Very common (10% or more): Rash
Common (1% to 10%): Ecchymosis, increased sweating, skin disorders
Uncommon (0.1% to 1%): Hair loss, skin eruptions
Frequency not reported: Facial hair, photosensitivity[Ref]
Very common (10% or more): Micturition disorder
Common (1% to 10%): Urinary retention
Frequency not reported: Hypersexuality, nocturia, penile sensation, prostatic hypertrophy, sexual dysfunction, slow urination, transient anorgasmia, urinary frequency, urinary hesitancy
Postmarketing reports: Increased libido[Ref]
Transient anorgasmia and decreased penile sensation were reported at doses greater than 10 mg per day. The estimates of the incidence of untoward sexual experience and performance may also underestimate their actual incidence, partly because patients and physicians may be reluctant to discuss this issue.[Ref]
Common (1% to 10%): ALT/AST increased
Uncommon (0.1% to 1%): Transient increase in liver enzyme values[Ref]
Very common (10% or more): Application site reactions (transdermal patch)[Ref]
The 1.25 mg orally disintegrating tablet contains 1.25 mg phenylalanine.
Anorexia was reported as a very common side effect with selegiline (the active ingredient contained in Eldepryl) in double-blind placebo-controlled clinical trials when used as adjunctive therapy with levodopa in the earlier phases of Parkinson's disease.[Ref]
Very common (10% or more): Anorexia
Uncommon (0.1% to 1%): Loss of appetite
Muscle twitch was reported at doses greater than 10 mg per day.[Ref]
Common (1% to 10%): Arthralgia, back pain, leg cramps, leg pain, low back pain, myalgia, musculoskeletal injuries, muscle cramps
Uncommon (0.1% to 1%): Myopathy
Frequency not reported: Muscle twitch, stiff neck
Postmarketing reports: Muscle weakness (myasthenia)[Ref]
Common (1% to 10%): Abnormal accommodation
Uncommon (0.1% to 1%): Blurred vision
Frequency not reported: Blepharospasm, diplopia
Postmarketing reports: Abnormal vision[Ref]
Frequency not reported: Melanoma[Ref]
Epidemiological studies have shown that Parkinson's disease patients are at a 2- to 6-fold increased risk of developing melanoma than the general population. It is unclear whether the observed increase in risk is due to Parkinson's disease or other factors.[Ref]
Small increments in serum BUN and creatinine were observed with high doses of orally disintegrating selegiline (the active ingredient contained in Eldepryl) (10 mg orally per day).[Ref]
Frequency not reported: Small increments in serum BUN and creatinine[Ref]
1. Montastruc JL, Chaumerliac C, Desboeuf K, Manika M, Bagheri H, Rascol O, LapeyreMestre M "Adverse drug reactions to selegiline: A review of the French Pharmacovigilance Database." Clin Neuropharmacol 23 (2000): 271-5
2. "Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.
3. Riley DE "Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline." Clin Neuropharmacol 25 (2002): 234-7
4. Boyson SJ "Psychiatric effects of selegiline." Arch Neurol 48 (1991): 902
5. Brodersen P, Philbert A, Gulliksen G, Stigard A "The effect of L-Deprenyl on on-off phenomena in Parkinson's disease." Acta Neurol Scand 71 (1985): 494-7
6. "Product Information. Eldepryl (selegiline)." Somerset Pharmaceuticals Inc, Tampa, FL.
7. Vezina P, Mohr E, Grimes D "Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects." Can J Neurol Sci 19 (1992): 142-6
8. Menza MA, Golbe LI "Hypomania in a patient receiving deprenyl (selegiline) after adrenal- striatal implantation for Parkinson's disease." Clin Neuropharmacol 11 (1988): 549-51
9. Kurlan R, Dimitsopulos T "Selegiline and manic behavior in Parkinson's disease." Arch Neurol 49 (1992): 1231
10. Ito D, Amano T, Sato H, Fukuuchi Y "Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease." J Neurol 248 (2001): 533-4
11. McGrath PJ, Stewart JW, Quitkin FM "A possible L-deprenyl induced hypertensive reaction." J Clin Psychopharmacol 9 (1989): 310-1
12. Sandler M, Glover V, Ashford A, Stern GM "Absence of "cheese effect" during deprenyl therapy: some recent studies." J Neural Transm 43 (1978): 209-15
13. Golbe LI "Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease." Neurology 39 (1989): 1109-11
Some side effects may not be reported. You may report them to the FDA.
More about Eldepryl (selegiline)
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- En Español
- 1 Review
- Drug class: dopaminergic antiparkinsonism agents
- FDA Alerts (1)